Transcranial low-level laser therapy in an in vivo model of stroke: Relevance to the brain infarct, microglia activation and neuroinflammation.
Débora D S VogelNancy N Ortiz-VillatoroNoemi S AraújoMárcia Jonathas Guimarães MarquesFlávio AimbireFúlvio A ScorzaCarla A ScorzaRegiane AlbertiniPublished in: Journal of biophotonics (2021)
Stroke is the main cause of death and functional disability. The available therapy affects only 5% of patients, and new therapeutic approaches have been constantly tested. Transcranial photobiomodulation (PBM) is promising for its neuroprotective effect on brain injuries. Thus, the present study investigated the PBM effects in an in vivo model of ischemic stroke induced by photothrombosis (PT). Five different groups of Wistar rats were submitted or not to a daily dose of fish oil or/and laser sessions for 2 months. The ischemia volume was evaluated by stereology; GFAP, Iba and NeuN by immunohistochemistry; TNF-α, IL-1β, IL-6, IL-10 and TGF-β by ELISA assay. PBM influenced both the lesion volume and the GFAP. Furthermore, PBM and Ω-3 or both reduced Iba RNAm. PBM reduced TNF-α, IL-1β, IL-6, brain damage, neuroinflammation and microglial activation, and it increased astroglial activity in peri-lesioned region after stroke.
Keyphrases
- cerebral ischemia
- atrial fibrillation
- white matter
- lipopolysaccharide induced
- resting state
- rheumatoid arthritis
- lps induced
- traumatic brain injury
- ejection fraction
- inflammatory response
- multiple sclerosis
- subarachnoid hemorrhage
- newly diagnosed
- blood brain barrier
- brain injury
- physical activity
- functional connectivity
- heart failure
- acute myocardial infarction
- acute coronary syndrome
- oxidative stress
- neuropathic pain
- left ventricular
- high throughput
- cerebral blood flow
- high resolution
- fatty acid
- atomic force microscopy
- cell therapy
- single molecule
- monoclonal antibody